Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Часто задаваемые вопросы
В каком секторе работает Silverback Therapeutics, Inc (SBTX)?
Silverback Therapeutics, Inc относится к сектору Здравоохранение.
Выплачивает ли Silverback Therapeutics, Inc (SBTX) дивиденды?
Нет, Silverback Therapeutics, Inc не выплачивает дивиденды.